Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test ...

Opening our new headquarters marks an important milestone for Castle Biosciences,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The facility was built to empower ...

Castle Biosciences, Inc. ( CSTL) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2025 Conference Call. As a reminder, ...

Castle Biosciences Inc (CSTL) reports robust revenue growth and strategic advancements, despite facing profitability and regulatory hurdles.

Castle Biosciences, Inc. (CSTL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...

Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

The average one-year price target for Castle Biosciences (NasdaqGM:CSTL) has been revised to $43.99 / share. This is an increase of 14.24% from the prior estimate of $38.50 dated December 18, 2025.

Short interest in Castle Biosciences Inc (NASDAQ:CSTL) increased during the last reporting period, rising from 1.52M to 1.80M. This put 7.13% of the company's publicly available shares short. Short ...

The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.